We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research. Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.
− Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99) – − Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators − − Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world – BELOIT, Wis.,
− Organizational change positions NorthStar for next stage of growth and ongoing U.S.
BELOIT, Wis., March 2, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C.
Questions about company, products, supply solutions, careers or anything else?